Interpace Biosciences, Inc. (IDXG)
| Market Cap | 18.51M |
| Revenue (ttm) | 26.45M |
| Net Income (ttm) | -33.55M |
| Shares Out | 4.03M |
| EPS (ttm) | -8.50 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 19 |
| Last Price | $4.58 |
| Previous Close | $4.10 |
| Change ($) | 0.48 |
| Change (%) | 11.71% |
| Day's Open | 4.33 |
| Day's Range | 4.15 - 4.70 |
| Day's Volume | 96,883 |
| 52-Week Range | 2.84 - 10.55 |
Parsippany, NJ, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) today announced that Jack Stover, President & Chief Executive Officer, will retire effective Decemb...
PARSIPPANY, NJ, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) on November 18, 2020 received notice from the Listing Qualifications...
Study Demonstrates Superior Performance of ThyGeNEXT ® and ThyraMIR ® vs. Other Molecular Tests
Year to Date Net Revenue of $14.6 Million Up 19% vs Prior Year; Second Quarter Net Revenue of $5.4 Million
Interpace Biosciences (IDXG) news for Wednesday includes a positive audit committee result giving IDXG stock a much-needed boost. The post Interpace Biosciences News: Why IDXG Stock Is Soaring...
PARSIPPANY, NJ, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (Nasdaq: IDXG) announced today that the Audit Committee of the Board of Directors h...
Podium Presentation Accepted for the American Society of Cytopathology (ASC) Annual Meeting
Interpace Biosciences, Inc. (IDXG) CEO Jack Stover on Q1 2020 Results - Earnings Call Transcript
First Quarter Net Revenue Improved Over 53% to $9.2 Million
In-Network Access for More Than 3 Million Members
Conference Call and Webcast Wednesday April 22, 2020 5:00 pm ET
Interpace Biosciences (NASDAQ: IDXG) provides complex molecular analysis for the early diagnosis and treatment of cancer.
Parsippany, NJ, March 11, 2020 (GLOBE NEWSWIRE) -- Interpace Diagnostics, a subsidiary of Interpace Biosciences (NASDAQ: IDXG) announced today that it has entered into a contract with Blue C...
In-Network Access for More Than 3 Million Members
Parsippany, NJ, March 02, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced acceptance of the first manuscript reporting the clinical performance of the com...
Parsippany, NJ, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that the Center for Medicare and Medicaid Services (CMS) has modified the reimbur...
PARSIPPANY, NJ, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences , Inc. (NASDAQ: IDXG) (“Interpace”) a leader in enabling personalized medicine, is pleased to announce today that Ron ...
With stocks at all time highs and after the Dow rose more than 22% and the S&P 500 rose over 28% in 2019, many investors have yet to make many changes in the portfolios for what could be anoth...
Underappreciated Drivers, Bargain Valuation, And Cash Infusion Set Interpace Up For Substantial Upside
Underappreciated Drivers, Bargain Valuation & Cash Infusion Set Interpace Up For Substantial Upside
Reverse Stock Split Planned Concurrent with Closing
Parsippany, NJ, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG), a leader in enabling personalized medicine, today announced that the Company’s wholly-owned subs...
Parsippany, NJ, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that its Medicare Administrative Contractor (MAC) has issued a new draft local co...
Further Strengthens Business Development Team with Key Hire
PARSIPPANY, NJ, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (IDXG) announced today that it is launching its new corporate website, “Interpace.com”. Now both the Diagnostics...
Interpace Diagnostics Group, Inc. (IDXG) CEO Jack Stover on Q3 2019 Results - Earnings Call Transcript
Third Quarter Revenue Grew 34% Over the Prior Year’s Quarter and 25% Year to Date
Clinical Data Highlights the Utility of ThyGeNEXT® and ThyraMIR®
PARSIPPANY, NJ, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Interpace (IDXG) announced today that it will be presenting new data on the performance of its molecular thyroid products at the upcoming 89...
Interpace hosts 2nd Annual Fellow Programs
PARSIPPANY, NJ, Oct. 17, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (IDXG) announced today that it has closed on a $13 million Convertible Preferred Stock investment by Amper...
PARSIPPANY, NJ, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has been named one of the 50 Most Admired Companies of the Year by ...
In-Network Access for Thyroid Assays for More than 5 Million Members
PARSIPPANY, NJ, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) today announced that the Company will present at the upcomi...
PARSIPPANY, NJ, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc.’s subsidiary, Interpace BioPharma Inc. (“Interpace”, “Interpace BioPharma” or the “Company”) today announ...
PARSIPPANY, NJ, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) today announced that the Company will present at the upcom...
Interpace Diagnostics Group, Inc. (IDXG) CEO Jack Stover on Q2 2019 Results - Earnings Call Transcript
Interpace Diagnostics Group, Inc. (IDXG) CEO Jack Stover on Q1 2019 Results - Earnings Call Transcript
Interpace Diagnostics Group, Inc. (IDXG) CEO Jack Stover on Q4 2018 Results - Earnings Call Transcript
About IDXG
Interpace Biosciences provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expressi... [Read more...]
| Industry Diagnostics & Research | IPO Date May 20, 1998 |
| CEO Nancy Lurker | Employees 176 |
| Stock Exchange NASDAQ | Ticker Symbol IDXG |
Financial Performance
In 2019, IDXG's revenue was $24.22 million, an increase of 10.61% compared to the previous year's $21.90 million. Losses were -$26.74 million, 110.5% more than in 2018.
Analyst Forecasts
According to 4 analysts, the average rating for IDXG stock is "Buy." The 12-month stock price forecast is 10.13, which is an increase of 121.18% from the latest price.